1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Eyenovia Open To All Strategic Option With Phase III Myopia Terminations

 
• By Joseph Haas

With its data monitoring committee saying a Phase III trial of a drug-device combo product in pediatric myopia was not on track for success, Eyenovia will end the study and consider its options.

Eye in an high tech environment
Eyenovia is giving up on its pediatric myopia combo product

Despite a three-product commercial portfolio, a technology platform that has yielded multiple licensing deals and an agreement with NovaBay to co-promote each other’s ophthalmic therapies, Eyenovia said on 15 November that it is considering all strategic options – including a merger or asset divestment – after deciding to discontinue the Phase III CHAPERONE study of MicroPine, its drug-device combination product being studied in pediatric progressive myopia.

Key Takeaways
  • Eyenovia learned its Phase III trial of a drug-device combo product for pediatric myopia is not on track to hit its primary endpoint. The company will end the study and consider strategic options.

The New York-based firm revealed that the study’s independent data review committee, upon reviewing available safety and efficacy data for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from Rare Diseases

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Early Blood Cancer Data Impresses As Incyte Plots Post-Jakafi Strategy

 
• By Kevin Grogan

First results for a first-in-class mutCALR-targeted therapy in essential thrombocythemia presented at EHA point to a lucrative future for the early-stage product.